Valuation: CS Diagnostics Corp.

Market Cap 17.5M 15.11M 14.2M 12.92M 24.28M 1.67B 24.68M 166M 65.07M 838M 65.7M 64.28M 2.78B P/E 2024
232,000x
P/E 2025 1,077x
Enterprise Value 17.49M 15.11M 14.2M 12.91M 24.27M 1.67B 24.68M 166M 65.04M 838M 65.68M 64.25M 2.78B EV / Sales 2024
1,357x
EV / Sales 2025 375x
Free-Float
14.55%
Yield 2024 *
-
Yield 2025 -
1 month+40.00%
3 months-41.62%
6 months-69.57%
Current year-77.12%
1 month 0.01
Extreme 0.0105
0.14
Current year 0.01
Extreme 0.0105
0.4
1 year 0.01
Extreme 0.0105
0.4
3 years 0.01
Extreme 0.0105
5.64
5 years 0.01
Extreme 0.0105
9
10 years 0.01
Extreme 0.0105
28.95
Manager TitleAgeSince
Chief Executive Officer 56 2022-03-31
Director of Finance/CFO 47 2021-12-31
Corporate Officer/Principal 45 2024-07-17
Director TitleAgeSince
Chairman 56 1996-09-24
Director/Board Member 47 2021-12-31
Director/Board Member 54 2025-08-31
Date Insider Type Main position Quantity % Market Cap.
12/31/25 Other

Chief Executive Officer

49,362,500 35.9418%
12/31/25 Other

Chief Executive Officer

104,507,800 76.0941%
12/31/25 Other

Chief Executive Officer

42,560,096 30.9888%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-36.36%0.00% 17.5M
-0.02%+3.19%-13.95%+4.85% 193B
+0.76%+4.72%-0.77%+9.75% 117B
+1.43%-2.07%+6.43%+67.25% 59.89B
+0.32%+3.92%+38.42%+65.14% 56.01B
+0.79%+3.70%-5.95%-35.11% 49.96B
-1.89%+5.90%+12.24%-22.47% 33.87B
+0.45%+1.45% - - 31.36B
+0.94%-1.31%+41.93%-12.62% 24.59B
+1.98%+12.62%-2.80%+25.91% 24.77B
Average +0.48%+3.32%+4.35%+11.41% 58.98B
Weighted average by Cap. +0.42%+3.41%+1.50%+13.55%

Financials

2024 2025
Net sales 111K 95.79K 90.02K 81.87K 154K 10.61M 156K 1.05M 412K 5.31M 416K 407K 17.65M 204K 176K 166K 151K 283K 19.51M 288K 1.94M 759K 9.77M 766K 749K 32.46M
Net income 761 657.28 617.64 561.71 1.06K 72.77K 1.07K 7.24K 2.83K 36.44K 2.86K 2.8K 121K 71.22K 61.51K 57.8K 52.57K 98.83K 6.81M 100K 677K 265K 3.41M 267K 262K 11.33M
Net Debt -501 -432.71 -406.62 -369.8 -695.25 -47.91K -706.71 -4.76K -1.86K -23.99K -1.88K -1.84K -79.72K -6.81K -5.88K -5.53K -5.03K -9.45K -651K -9.61K -64.79K -25.33K -326K -25.58K -25.02K -1.08M
Logo CS Diagnostics Corp.
CS Diagnostics Corp is a Germany-based medical technology and distribution company. The Company is focused on developing and commercializing therapeutic and preventive solutions to improve patient care and outcomes. Its primary products are CS Protect-Hydrogel, a tissue spacer gel designed for use in radiation therapy, and MEDUSA, a surface disinfectant. CS Protect Hydrogel is an injectable organ spacer initially targeted for prostate cancer radiotherapy, where it increases the distance between the prostate tumor and the rectum to reduce radiation damage to healthy tissue. It is ready-to-use (pre-mixed in a sterile package) rather than requiring on-site mixing by clinicians. MEDUSA’s formulation provides an extended duration of antimicrobial protection on surfaces. It includes color-changing test strips that allow users to verify the concentration of the active ingredient over time.
Employees
1
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. CSDX Stock